calendar
2,132 catalysts · 3,827 phase readout · 2,121 8k filing · 277 earnings · 172 phase 2 completion · 133 drug shortage · 109 grant
next 91 dayslessmore
MonWedFri
2,132 catalysts · 3,827 phase readout · 2,121 8k filing · 277 earnings · 172 phase 2 completion · 133 drug shortage · 109 grant
Items: 7.01, 9.01
Items: 5.02, 7.01, 9.01
Items: 1.01, 8.01, 9.01
Items: 7.01, 8.01, 9.01
Items: 5.02, 9.01
Items: 5.02, 9.01
Items: 1.02
Items: 8.01
Items: 8.01
Items: 2.02, 7.01, 9.01
Items: 5.02
Items: 5.02, 5.07, 9.01
Items: 7.01, 8.01, 9.01
Items: 5.02, 7.01, 9.01
Items: 2.02, 9.01
Items: 8.01
Items: 7.01, 9.01
Items: 1.01, 7.01, 8.01, 9.01
Items: 5.02, 7.01, 9.01
Items: 7.01, 9.01
Items: 1.02, 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 9.01
Therapy area: Infectious Disease, Respiratory. Indication: Asthma, Influenzavirus A Infections, Influenzavirus B Infections
Therapy area: Gastrointestinal, Infectious Disease, Oncology. Indication: Acral Lentiginous Melanoma, Adenocarcinoma Of The Gastroesophageal Junction, Adenoid Cystic Carcinoma (ACC), Adrenocortical Carcinoma (Adrenal Cortex Cancer), Anaplastic Thyroid Cancer, Bile Duct Cancer (Cholangiocarcinoma), Bladder Cancer, Breast Cancer, Colorectal Cancer, Cutaneous Squamous Cell Carcinoma (cSCC), Endometrial Cancer, Ependymoma, Epithelial Ovarian Cancer, Esophageal Squamous Cell Carcinoma (ESCC), Ewing S
Items: 1.01, 7.01, 9.01
Items: 1.01, 9.01
Items: 3.01
Items: 5.02
Items: 8.01, 9.01
Items: 5.02, 9.01
Items: 1.01, 2.03, 9.01
Items: 5.02, 9.01
Items: 1.01, 3.01, 9.01
Items: 8.01, 9.01
Items: 5.02
Items: 5.02, 9.01
Items: 1.01, 8.01, 9.01
Items: 5.02
Items: 5.02
Items: 1.01, 2.01, 3.02, 9.01
Items: 9.01
Items: 5.07
Items: 1.01, 8.01, 9.01
Items: 1.01, 3.02, 9.01
Items: 1.01, 9.01
Items: 5.03, 9.01
Items: 1.01, 9.01
Items: 5.02, 9.01
Items: 2.03
Items: 7.01, 8.01, 9.01
Items: 2.04